News, info and tips for living with multiple sclerosis

Tolebrutinib nears the MS approval finish line

Woman runs toward finish line, like tolebrutinib is

After some stumbles out of the starting gate, an experimental treatment that’s in a group hoping to be the next big thing for people with multiple sclerosis (MS) is a step closer to U.S. Food and Drug Administration (FDA) approval. Tolebrutinib, developed by Sanofi, has been designated as a Breakthrough Therapy for the treatment of adults with non-relapsing secondary progressive MS (nrSPMS). The designation is intended to speed the development…Continue Reading

A Little Stumble for BTKi’s

BTK's are molecules

A little over a year ago, I wrote about whether Bruton’s tyrosine kinase inhibitors (BTKi’s) might be the next big thing in multiple sclerosis (MS) treatments. BTKi’s are small molecules that selectively block an enzyme that’s important for the activation of B-cells in the immune system and microglia, cells whose job is to protect neurons. Some of both types of cells are thought to be responsible for the abnormal immune…Continue Reading